Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Pfizer 3Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Pfizer 3Q

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Pfizer

3Q Revenues: $12.0 billion (-2%)

3Q Earnings: $761 million (-77%)

YTD Revenues: $35.6 billion (-1%)

YTD Earnings: $5.4 billion (-45%)

Comments: 3Q Pharma sales dropped 4% to $11.0 billion. Ongoing generic erosion from Zoloft (June 2006) and Norvasc (March 2007) hurt revenues for 3Q and YTD. Sales for those products dropped from $1.6 billion in 3Q06 to $764 million in 3Q07 and $5.5 billion YTD06 to $2.8 billion in YTD07. Lipitor sales decreased 5% to $3.2 billion due to competition from generic statins. Lyrica sales grew 37% to $465 million and  Chantix grew from $33 million to $241 million. Earnings were pounded by a $2.8 billion writeoff from the company’s decision to drop Exubera inhaled insulin.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters